Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S32-S42
Open Access | Times Cited: 328

Showing 1-25 of 328 citing articles:

Noninvasive Assessment of Liver Fibrosis in NAFLD
Arun J. Sanyal, Laurent Castéra, Vincent Wai‐Sun Wong
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2026-2039
Closed Access | Times Cited: 71
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
Farah Abdelhameed, Chris Kite, Lukasz Lagojda, et al.
Current Obesity Reports (2024) Vol. 13, Iss. 3, pp. 510-531
Open Access | Times Cited: 37
WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
Giovanna Ferraioli, R. Graham Barr, Annalisa Berzigotti, et al.
Ultrasound in Medicine & Biology (2024) Vol. 50, Iss. 8, pp. 1071-1087
Closed Access | Times Cited: 33
Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up
Hun Jee Choe, Joon Ho Moon, Won Kim, et al.
Metabolism (2024), pp. 155800-155800
Closed Access | Times Cited: 27
NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
Natalia G. Vallianou, Dimitris Kounatidis, Sotiria Psallida, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 366-366
Open Access | Times Cited: 23
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
M H Miran Beygi, Salma Ahi, Samaneh Zolghadri, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2220-2220
Open Access | Times Cited: 18
Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank
Yanan Qiao, Yue Wang, Chen Cheng, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Liver diseases: epidemiology, causes, trends and predictions
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review
Haider Ghazanfar, Nismat Javed, Abeer Qasim, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1214-1214
Open Access | Times Cited: 15
Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease
Saira Rafaqat, Sanja Gluščević, Filiz Mercantepe, et al.
Metabolites (2024) Vol. 14, Iss. 3, pp. 153-153
Open Access | Times Cited: 13
NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Geladari, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 826-826
Open Access | Times Cited: 13
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
Ahmed Samy, Mohamed A. Kandeil, Dina Sabry, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e30387-e30387
Open Access | Times Cited: 13
Amino acid is a major carbon source for hepatic lipogenesis
Yilie Liao, Qishan Chen, Lei Liu, et al.
Cell Metabolism (2024) Vol. 36, Iss. 11, pp. 2437-2448.e8
Open Access | Times Cited: 13
Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
Kamila Kasprzak‐Drozd, Przemysław Niziński, Paulina Kasprzak, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3746-3746
Open Access | Times Cited: 12
A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
Byung-Kwan Jeong, Won‐Il Choi, Won Suk Choi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases
Genshan Zhang, Wei Jiang, Fangxun He, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 10
Evolving global etiology of hepatocellular carcinoma (HCC): Insights and trends for 2024.
Abraham Koshy
Journal of Clinical and Experimental Hepatology (2024) Vol. 15, Iss. 1, pp. 102406-102406
Closed Access | Times Cited: 9
Association between non-alcoholic fatty liver disease and progression of abdominal aortic aneurysm: a multicenter study
Ximing Wang, Jingxiang Sun, Na Chang, et al.
BMC Medical Imaging (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
Xin Qiu, Shuang Shen, Nizhen Jiang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
Catherine Stankevicius, R H Davis, Dep Huynh, et al.
Journal of Digestive Diseases (2025)
Closed Access | Times Cited: 1
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies
Maria V. Bourganou, Maria Chondrogianni, Ioannis Kyrou, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1589-1589
Open Access | Times Cited: 1
Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management
Mariangela Rondanelli, Sara Borromeo, Alessandro Cavioni, et al.
Metabolites (2025) Vol. 15, Iss. 2, pp. 127-127
Open Access | Times Cited: 1
Multivitamin supplementation and its impact in metabolic dysfunction-associated steatotic liver disease
Tom Ryu, Seung Yun Chae, Jae Jun Lee, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
Ana G. Petrovic, Dunja Igrec, Karla Rožac, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 6, pp. 4544-4556
Open Access | Times Cited: 22
The silent burden of non‐alcoholic fatty liver disease in the elderly: A global burden of disease analysis
Pojsakorn Danpanichkul, Cheng Han Ng, Mark Muthiah, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 10, pp. 1062-1074
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top